Chiara Tarantelli, Lu Zhang, Elisabetta Curti, Eugenio Gaudio, Filippo Spriano, Valdemar Priebe, Luciano Cascione, Alberto J. Arribas, Emanuele Zucca, Davide Rossi, Anastasios Stathis, Francesco Bertoni. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. haematol [Internet]. 2019Jun.30 [cited 2024Apr.19];104(7):e307-e309. Available from: https://haematologica.org/article/view/8987